DGX:NYE-Quest Diagnostics Incorporated (USD)

COMMON STOCK | Diagnostics & Research |

Last Closing

USD 155.48

Change

+0.10 (+0.06)%

Market Cap

USD 17.18B

Volume

0.44M

Analyst Target

USD 138.69
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to physicians, hospitals, patients and consumers, health plans, government agencies, employers, retailers, pharmaceutical companies and insurers, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile phlebotomists, nurses, and other health and wellness professionals. The company also provides risk assessment services for the life insurance industry; and healthcare organizations and clinicians information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-18 )

Largest Industry Peers for Diagnostics & Research

Symbol Name Price(Change) Market Cap
DHR Danaher Corporation

-0.57 (-0.21%)

USD 199.35B
IQV IQVIA Holdings Inc

+2.69 (+1.12%)

USD 43.52B
A Agilent Technologies Inc

+0.66 (+0.48%)

USD 39.94B
LH Laboratory Corporation of Amer..

+0.21 (+0.09%)

USD 18.96B
CRL Charles River Laboratories

-0.11 (-0.05%)

USD 10.65B
QGEN Qiagen NV

+0.02 (+0.04%)

USD 10.30B
VNRX Volitionrx Ltd

-0.05 (-7.58%)

USD 0.06B
ENZ Enzo Biochem Inc

-0.01 (-0.89%)

USD 0.06B
TMO Thermo Fisher Scientific Inc

-0.37 (-0.06%)

N/A
MTD Mettler-Toledo International I..

+19.22 (+1.39%)

N/A

ETFs Containing DGX

GERM 6.72 % 0.00 %

N/A

N/A
EDOC Global X Telemedicine & D.. 4.32 % 0.00 %

-0.10 (0%)

USD 0.04B
DDOC:XETRA Global X Telemedicine & D.. 4.30 % 0.00 %

-0.09 (0%)

USD 5.39M
DDOC:F Global X Telemedicine & D.. 4.30 % 0.00 %

+0.07 (+0%)

USD 4.62M
EDOG:LSE Global X Telemedicine & D.. 4.26 % 0.00 %

-0.10 (0%)

USD 0.22M
EDOC:LSE Global X Telemedicine & D.. 4.25 % 0.00 %

-0.11 (0%)

USD 3.75M
EDOC:SW Global X Telemedicine & D.. 4.04 % 0.00 %

-0.10 (0%)

N/A
OWLU:LSE 2.44 % 0.00 %

N/A

N/A
BSMC 2.10 % 0.00 %

N/A

N/A
RYH 0.00 % 0.40 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Diagnostics & Research) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 12.76% 69% C- 68% D+
Dividend Return 1.60% 86% B+ 37% F
Total Return 14.37% 77% C+ 66% D+
Trailing 12 Months  
Capital Gain 24.37% 100% F 75% C
Dividend Return 2.34% 86% B+ 36% F
Total Return 26.71% 100% F 74% C
Trailing 5 Years  
Capital Gain 44.74% 42% F 69% C-
Dividend Return 11.88% 100% F 43% F
Total Return 56.62% 67% D+ 69% C-
Average Annual (5 Year Horizon)  
Capital Gain 6.31% 38% F 60% D-
Dividend Return 8.28% 38% F 58% F
Total Return 1.97% 100% F 44% F
Risk Return Profile  
Volatility (Standard Deviation) 16.74% 92% A 60% D-
Risk Adjusted Return 49.44% 69% C- 67% D+
Market Capitalization 17.18B 56% F 90% A-

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Underpriced on cashflow basis

The stock is trading low compared to its peers on a price to cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Underpriced on free cash flow basis

The stock is trading low compared to its peers on a price to free cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector